NICE Recommends Gedeon Richter’s Ryeqo for Uterine Fibroids
Relugolix
The UK’s National Institute for Health and Care Excellence (NICE) is recommending Gedeon Richter’s Ryeqo (relugolix, estradiol and norethisterone acetate) for National Health Service use for treating patients with moderate-to-severe uterine fibroid symptoms.
Symptoms of uterine fibroids can include prolonged heavy menstrual bleeding, pelvic pain and pressure and fertility problems.
The oral drug, which can be taken at home, “has the potential to improve quality of life,” said Helen Knight, interim director of medicines evaluation at the NICE Center for Health Technology Evaluation.
In the U.S., Ryeqo is branded as Myfembree and sold under license by Myovant Sciences and Pfizer.
May 16, 2022
